CONTEXT: Report of a retrospective RWD study into the impact of race and ethnicity in oncology research. As we have reported here previously, there is an real issue with under-representation of minorities in the development process for new treatments which will impact on how these patients are ultimately managed.
IMPACT: high
READ TIME: 3 mins
Quality Level Mean [1 – 10]: 8
1. “The objective of this study is to evaluate the impact of race and ethnicity on treatment response in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-1 or PD-L1 inhibitors through analysis of real-world data (RWD).”
2. “RESULTS: After a median follow-up of 14.8 months, median TTD was 7.8 months (95% confidence interval 5.4 – not estimable [NE]) in 75 African American patients vs. 4.6 (2.4 – 7.2) in 110 White patients (hazard ratio [HR] 0.63).”
3. “Further investigation revealed the African American group had lower incidence (14.7%) of putative hyperprogressive diseases (HPD) upon anti-PD1/PD-L1 treatment than the White patient group (24.5%).”
4. “CONCLUSIONS: Analysis of RWD showed longer TTD and OS in African American aNSCLC patients treated with anti-PD1/PD-L1 inhibitors.”
5. “In retrospective analysis of advanced non-small cell lung cancer patients treated with PD-1 or PD-L1 inhibitors, African American patients had significantly longer time-to-treatment discontinuation and longer overall survival.”